

2017

Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling

Robert D. Guzy

Washington University School of Medicine in St. Louis

Ling Li

Washington University School of Medicine in St. Louis

Craig Smith

Washington University School of Medicine in St. Louis

Samuel J. Dorry

University of Chicago

Hyun Young Koo

University of Chicago

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Guzy, Robert D.; Li, Ling; Smith, Craig; Dorry, Samuel J.; Koo, Hyun Young; Chen, Lin; and Ornitz, David M., "Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling." *The Journal of Biological Chemistry*.292,25. 10364-10378. (2017).

https://digitalcommons.wustl.edu/open_access_pubs/6096

Authors

Robert D. Guzy, Ling Li, Craig Smith, Samuel J. Dorry, Hyun Young Koo, Lin Chen, and David M. Ornitz



Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling

Received for publication, April 18, 2017. Published, Papers in Press, May 9, 2017. DOI 10.1074/jbc.M117.791764

Robert D. Guzy^{‡S1}, Ling Li^S, Craig Smith^S, Samuel J. Dorry[‡], Hyun Young Koo[‡], Lin Chen[¶], and David M. Ornitz^S

From the [‡]Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois 60637, the ^SDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri 63110, and the [¶]Department of Rehabilitation Medicine, Center of Bone Metabolism and Repair, State Key Laboratory of Trauma, Burns, and Combined Injury, Daping Hospital, Third Military Medical University, Chongqing 400042, China

Edited by Dennis R. Voelker

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive pulmonary scarring, decline in lung function, and often results in death within 3–5 years after diagnosis. Fibroblast growth factor (FGF) signaling has been implicated in the pathogenesis of IPF; however, the mechanism through which FGF signaling contributes to pulmonary fibrosis remains unclear. We hypothesized that FGF receptor (FGFR) signaling in fibroblasts is required for the fibrotic response to bleomycin. To test this, mice with mesenchyme-specific tamoxifen-inducible inactivation of FGF receptors 1, 2, and 3 (*Col1 α 2-CreER*; *TCKO* mice) were lineage labeled and administered intratracheal bleomycin. Lungs were collected for histologic analysis, whole lung RNA and protein, and dissociated for flow cytometry and FACS. Bleomycin-treated *Col1 α 2-CreER*; *TCKO* mice have decreased pulmonary fibrosis, collagen production, and fewer α -smooth muscle actin-positive (α SMA+) myofibroblasts compared with controls. Freshly isolated *Col1 α 2-CreER*; *TCKO* mesenchymal cells from bleomycin-treated mice have decreased collagen expression compared with wild type mesenchymal cells. Furthermore, lineage labeled FGFR-deficient fibroblasts have decreased enrichment in fibrotic areas and decreased proliferation. These data identify a cell autonomous requirement for mesenchymal FGFR signaling in the development of pulmonary fibrosis, and for the enrichment of the *Col1 α 2-CreER*-positive (*Col1 α 2+*) mesenchymal lineage in fibrotic tissue following bleomycin exposure. We conclude that mesenchymal FGF signaling is required for the development of pulmonary fibrosis, and that therapeutic strategies aimed directly at mesenchymal FGF signaling could be beneficial in the treatment of IPF.

Pulmonary fibrosis is characterized by progressive scarring of the lung, with abnormal production of extracellular matrix by activated fibroblasts, or myofibroblasts (1). In idiopathic pul-

monary fibrosis (IPF),² the cause of fibroblast activation and matrix deposition is unknown, although it is suggested to be a result of aberrant healing from an injury of unknown origin (2). IPF affects ~50,000 patients annually in the United States, and the median survival is 3–5 years after diagnosis (1). Recently approved novel antifibrotic agents Nintedanib (Ofev) and Pirfenidone (Esbriet) decrease the rate of decline in lung function and improve survival in IPF (3, 4); however, overall outcomes remain poor.

Fibroblast growth factors (FGFs) are implicated in the pathogenesis of pulmonary fibrosis. The receptor tyrosine kinase activity of FGF receptors (FGFRs) is inhibited by Nintedanib (5, 6), which decreases bleomycin-induced fibrosis in mice (7, 8). Inhibition of FGF signaling using a soluble ectodomain of FGFR2c decreased TGF- β 1 induced primary lung fibroblast proliferation and differentiation *in vitro*, as well as bleomycin-induced fibrosis *in vivo* (9). This ectodomain inhibits multiple FGFs known to bind to the IIIc splice variant of FGFR2, including FGFs 1, 2, 4, 6, 8, 9, 17, and 18 (10). A recent study demonstrated altered FGFR1 and FGF1 expression in IPF lungs, and suggested that FGF signaling is critical for fibroblast migration in pulmonary fibrosis (11). Additionally, administration of a specific inhibitor of FGFR1 (NP603) inhibits carbon tetrachloride-induced hepatic fibrosis in rats (12). Although these studies have demonstrated the importance of FGF signaling in the pathogenesis of pulmonary fibrosis, the cellular mechanisms involved remain elusive. In particular, it is not known which cell type(s) are critical targets for FGFs in the pathogenesis of pulmonary fibrosis *in vivo*.

In primary human lung fibroblasts, administration of TGF- β 1 induced FGF receptor expression (13) and FGF2 expression and secretion into culture media (14, 15). Primary lung fibroblasts isolated from rats exposed to peplomycin, a bleomycin-related compound, have increased FGF2 production (16). TGF- β 1-induced ERK, JNK, and AP-1 phosphorylation (14, 15), fibroblast differentiation into myofibroblasts, proliferation (17), and FGF2 production (18) are inhibited by FGF2-neutralizing antibodies, suggesting a cooperative mech-

This work was supported, in whole or in part, by National Institutes of Health Grants HL111190 and T32HL007317, American Heart Association Grant 14FTF19840029, Washington University Hope Center Alafi Neuroimaging Lab, and a National Institutes of Health Shared Instrumentation Grant S10 RR027552. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

¹ To whom correspondence should be addressed: 5841 S. Maryland Ave., MC6076, Chicago, IL 60637. Tel.: 773-702-6790; Fax: 773-702-6500; E-mail: rguzy1@bsd.uchicago.edu.

² The abbreviations used are: IPF, idiopathic pulmonary fibrosis; TCKO, triple conditional knockout; α SMA, α smooth muscle actin; PDGFR α , platelet-derived growth factor receptor α ; TFF, triple flox/flox; P21, postnatal day 21; EdU, 5-ethynyl-2-deoxyuridine; qRT, quantitative RT; pro-SPC, pro-surfactant protein C.




Figure 1. Localization of the Col1 α 2-CreER lineage and enrichment in fibrotic areas post-bleomycin. Col1 α 2-CreER; ROSA26^{mTmG/+} mice were treated with tamoxifen at P21 and lungs were collected for frozen sections and imaged with direct fluorescence microscopy (A and B). Arrows indicate primary sites of Col1 α 2+ peribronchiolar, perivascular, and interstitial cells. Frozen sections were stained for PDGFR α (C), Periostin (D), α SMA (E), and pro-SPC (F), and microscopy was performed for co-localization with GFP. Tamoxifen-treated Col1 α 2-CreER; ROSA26^{mTmG/+} mice were given a single dose of intratracheal bleomycin, and lungs were analyzed after 14 (G) and 21 days (H) for GFP fluorescence. Co-immunofluorescence for α SMA and GFP (I) was performed on 21-day post-bleomycin lung sections.

anism between FGF2 and TGF- β 1. These data suggest that FGF signaling in fibroblasts is critical in the pathogenesis of pulmonary fibrosis.

To test whether FGF signaling in lung mesenchyme and fibroblasts is required for the pathogenesis of pulmonary fibrosis *in vivo*, we have generated mice with a mesenchyme-specific inducible knock-out of FGF receptors 1, 2, and 3 using mice with tamoxifen-inducible Cre recombinase driven by the promoter for procollagen I α 2 (Col1 α 2-CreER) (19–21). Simultaneous deletion of multiple FGF receptors was performed due to overlapping receptor specificity of many FGFs, including FGF1, FGF2, and FGF9 (22), as well as simultaneous expression of multiple FGFRs in lung mesenchyme *in vivo*.

In this report we demonstrate that the Col1 α 2+ lineage is enriched in fibrotic tissue following bleomycin treatment, and that cell-autonomous FGFR signaling is required for this lineage enrichment. Deletion of FGFRs in lung mesenchyme decreases collagen expression and the development of pulmonary fibrosis in response to bleomycin. Our data suggests that inhibition of FGFR signaling pathways in fibroblasts slows the enrichment of lung mesenchyme into injured areas, providing a mechanistic rationale for the use of FGF inhibitors to slow the progression of pulmonary fibrosis.

Results

Gene expression in lung mesenchyme and fibroblasts

Mesenchymal cells were genetically tagged with a membrane-localized green fluorescent protein (GFP) by mating Col1 α 2-CreER mice with ROSA26^{mTmG} Cre reporter mice (23). Tamoxifen treatment of Col1 α 2-CreER; ROSA26^{mTmG/+} mice

from postnatal day 21 (P21) to P35 labels peribronchiolar smooth muscle and fibroblasts, perivascular smooth muscle, and interstitial fibroblasts (Fig. 1, A and B). Co-immunofluorescence for GFP and PDGFR α reveals that interstitial fibroblasts targeted by Col1 α 2-CreER are PDGFR α + (Fig. 1C). Col1 α 2+ (GFP+) mesenchymal cells also express periostin and α -smooth muscle actin (α SMA) (Fig. 1, D and E), but not s100a4 (not shown) and epithelial-specific proteins such as pro-surfactant protein C (pro-SPC) (Fig. 1F). In response to bleomycin, lung mesenchymal cells targeted by Col1 α 2-CreER were enriched in areas of fibrosis as early as 14 days post-bleomycin treatment (Fig. 1, G and H). Col1 α 2+ cells in areas of fibrosis express α SMA (Fig. 1I), although not all α SMA+ cells in fibrotic areas were GFP+.

Col1 α 2+ cells make up $3.97 \pm 0.54\%$ ($n = 8$) of all single cells from Col1 α 2-CreER; ROSA26^{mTmG/+} mice treated with tamoxifen (Fig. 2, A–D), and 32% of CD45, CD31, EpCAM (Lin-negative) cells (Fig. 2G). Very few Col1 α 2+ cells are found in the Lin-positive population (Fig. 2F). GFP+ cells were collected from tamoxifen-treated mouse lungs by cell sorting, and expression of mesenchymal-specific genes was measured using quantitative RT-PCR and normalized to GAPDH and whole lung expression. Col1 α 2+ mesenchymal cells were highly enriched for Col1 α 1, Col1 α 2, Acta2, Periostin, and PDGFR α (Fig. 2H).

Fgfr1 is expressed in mesenchymal cells and fibroblasts (22). In IPF, expression of FGFRs 1–3 is increased in myofibroblasts (11). To determine the potential for redundant function of Fgfr2, Fgfr3, and Fgfr4 in mesenchymal cells and fibroblasts, we measured Fgfr expression in freshly isolated (non-cultured) Col1 α 2+ mesenchymal cells. Analysis of Fgfr expression showed that Fgfr1

Fibroblast-specific FGFR signaling in pulmonary fibrosis




Figure 2. Isolation and gene expression of *Col1α2*+ mesenchymal cells. Tamoxifen-treated *Col1α2-CreER; ROSA26^{mTmG/+}* mouse lungs were harvested, enzymatically dissociated, and GFP+ cells were identified via flow cytometry. Single cells were identified using forward and side scatter (A and B), and GFP+ cells were identified (D). Analysis of Cre-negative *ROSA26^{mTmG/+}* mouse lungs was used to confirm gating (C). Dissociated lungs were stained with BV421-conjugated antibodies against CD31, CD45, and EpCAM (Lin) (E), and abundance of GFP+ cells was measured in both Lin-positive (F) and Lin-negative (G) populations. PE, phycoerythrin. Total RNA was purified from freshly sorted GFP+ cells and analyzed via quantitative RT-PCR for expression of *Fgfr1*, *Col1α1*, *Col1α2*, *Acta2*, *Periostin*, *Pdgfra*, *Fgfr2*, *Fgfr3*, and *Fgfr4* (H and I). GFP+ cells were cultured, and RNA was collected from passage number 2 cells for qRT-PCR analysis of *Fgfr1*, *Fgfr2*, *Fgfr3*, and *Fgfr4* (J). qRT-PCR data were normalized to *Gapdh* and expressed as ΔC_t . * indicates $p < 0.05$ compared with whole lung RNA.

is the predominant FGF receptor expressed in *Col1α2*+ cells. *Fgfr2*, *Fgfr3*, and *Fgfr4* were expressed at ~16-, 2.15-, and 2.82-fold lower levels than *Fgfr1*, respectively (Fig. 2J).

When *Col1α2*+ mesenchymal cells were cultured on collagen-coated dishes, *Fgfr1* remained the most abundant FGFR, however, expression of *Fgfr2* and *Fgfr3* was significantly diminished by passage number 2, and there was little measurable *Fgfr4* expression (Fig. 2J). These data indicate that to completely inhibit FGF signaling in lung mesenchyme *in vivo*, deletion of multiple FGFRs is necessary, as they are capable of compensatory signaling if only *Fgfr1* is deleted.

Generation of mesenchyme-specific FGF receptor knock-out mice

Given significant expression of multiple FGF receptors in lung mesenchyme *in vivo*, we generated mesenchyme-specific

knock-out of *Fgfrs 1, 2, and 3* using the *Col1α2-CreER* allele. *Col1α2-CreER* mice were crossed with *Fgfr1^{fl/fl}*; *Fgfr2^{fl/fl}*; *Fgfr3^{fl/fl}* triple flox mice (*Fgfr1/2/3 TFF*). Successful generation of *Col1α2-CreER; Fgfr1/2/3 TFF* mice was confirmed by PCR (Fig. 3A). Treatment of *Col1α2-CreER; Fgfr1/2/3 TFF* mice with tamoxifen from P21 to P35 generated triple conditional knock-out mice (*Col1α2-CreER; TCKO*) with significant reduction in *Fgfr1*, -2, and -3 expression in freshly sorted *Col1α2*+ mesenchymal cells (Fig. 3B). Expression of *Fgfr4* was unchanged in *Col1α2-CreER; TCKO* mice (Fig. 3B). Baseline expression, as expressed by ΔC_t , of mesenchyme-specific genes such as *Col1α1*, *Col1α2*, *Col3α1*, *Fibronectin*, *Pdgfra*, α -smooth muscle actin (*Acta2*), *Periostin* (*Postn*), *Lysyl oxidase* (*Lox*), *s100a4*, and connective tissue growth factor (*Ctgf*) were also unchanged in freshly sorted *Col1α2-CreER; TCKO* mesenchyme compared with controls (Fig. 3C). The predominant mesenchymal genes




Figure 3. Generation of mesenchyme-specific *Fgfr1/2/3* triple conditional knock-out mice. Successful generation of *Fgfr1^{f/f}*; *Fgfr2^{f/f}*; *Fgfr3^{f/f}* (*Fgfr1/2/3* TFF) mice was confirmed by PCR (A). Tamoxifen-treated *Col1α2-CreER; Fgfr1/2/3* TFF; *ROSA26^{mTmG/+}* (to generate *Col1α2-CreER; TCKO; ROSA26^{mTmG/+}*) and *Col1α2-CreER; ROSA26^{mTmG/+}* control mouse lungs were harvested, dissociated, and GFP+ cells were collected via cell sorting. Total RNA was purified from freshly sorted GFP+ cells and analyzed via quantitative RT-PCR for *Fgfr1*, *Fgfr2*, *Fgfr3*, and *Fgfr4* (B), as well as *Col1α1*, *Col1α2*, *Col3α1*, *Fibronectin*, *Pdgfra*, *Postn*, *Acta2*, *Lox*, *s100a4*, and *Ctgf* (C). Data were normalized to *Gapdh* and expressed as ΔC_t . * indicates $p < 0.05$.

expressed in freshly sorted *Col1α2*+ cells were *Col1α1* and *Col3α1* (Fig. 3C).

To determine whether lung mesenchyme from *Col1α2-CreER; TCKO* mice have deficient FGF signaling, sorted GFP+ cells (*Col1α2*+ lineage) from tamoxifen-treated *Col1α2-CreER; TCKO; ROSA26^{mTmG/+}* and *Col1α2-CreER; ROSA26^{mTmG/+}* mice were cultured and administered recombinant FGF2 (2 nM) for 48 h. *Col1α2-CreER; TCKO* mesenchymal cells have decreased expression of FGF-dependent genes *Etv4* and *Spry2* at baseline and in response to FGF2 (Fig. 4, A and B). Additionally, *Etv4* expression was significantly decreased in whole lung RNA and in RNA from freshly sorted GFP+ cells from bleomycin-treated *Col1α2-CreER; TCKO; ROSA26^{mTmG/+}* mice compared with controls (Fig. 4, C and D). Western blot analysis from whole-lung protein lysates demonstrated decreased phosphorylation of ERK1/2 in bleomycin-treated *Col1α2-CreER; TCKO* mice compared with controls (Fig. 5, A and B). Additionally, co-immunofluorescence for phosphorylated ERK1/2 and GFP demonstrated decreased phosphorylation of ERK1/2 overall and in GFP+ cells (Fig. 5, C–J) in bleomycin-treated *Col1α2-CreER; TCKO; ROSA26^{mTmG/+}* mice compared with *Col1α2-CreER; ROSA26^{mTmG/+}* controls, indicating decreased FGFR-dependent activation of p42/44 MAPK pathways. These data show that mesenchymal cells from *Col1α2-CreER; TCKO* mice have deficient FGF-induced signaling and gene expression.

Decreased bleomycin-induced pulmonary fibrosis in mesenchyme-specific FGFR knock-out mice

To test whether deletion of FGF receptors in mesenchyme alters the development of pulmonary fibrosis in response to bleomycin, *Col1α2-CreER; TCKO* mice and Cre-negative *Fgfr1/2/3* TFF controls were treated with tamoxifen (to generate *Col1α2-CreER; TCKO* and control mice) and subsequently administered a single dose of intratracheal bleomycin (1.2 units/kg). *Col1α2-CreER; TCKO* mice had attenuated weight loss post-bleomycin (Fig. 6A) and improved survival (Fig. 6B). Histologic analysis revealed significantly decreased bleomycin-induced pulmonary fibrosis in *Col1α2-CreER; TCKO* mice compared with triple flox/flox (TFF) controls 21 days after bleomycin on H&E-stained sections (Fig. 6D), by Ashcroft scoring (Fig. 6C), and on Masson trichrome-stained sections (Fig. 6F). Quantitative hydroxyproline measurements revealed decreased collagen deposition in *Col1α2-CreER; TCKO* mice 21 days post-bleomycin (Fig. 6E). There was no difference in histologic fibrosis or hydroxyproline content between Cre-negative TFF controls and mice containing only *Col1α2-CreER* (Cre controls) in response to bleomycin (not shown).

To test whether mesenchyme-specific deletion of FGFRs is required for bleomycin-induced expansion of myofibroblasts, lungs from *Col1α2-CreER; TCKO* and *Col1α2-CreER* control mice treated with intratracheal bleomycin were enzymatically

Fibroblast-specific FGFR signaling in pulmonary fibrosis




Figure 4. Decreased downstream FGFR signaling in *Col1α2-CreER*; *TCKO* mesenchymal cells. *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* and *Col1α2-CreER*; *ROSA26^{mTmG/+}* mouse lungs were harvested, dissociated, and GFP⁺ cells were collected via FACS and cultured for 2 passages. Cultured mesenchymal cells were treated with recombinant FGF2 (2 nM) for 48 h and total RNA was collected for quantitative RT-PCR analysis of *Spry2* (A) and *Etv4* (B). *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* and *Col1α2-CreER*; *ROSA26^{mTmG/+}* mice were treated with intratracheal bleomycin, RNA was collected from whole lungs (C) or GFP⁺ cells isolated via FACS (D), and analyzed by qRT-PCR for *Etv4* expression. Data were normalized to *Gapdh* and expressed as fold-change from untreated control. * indicates $p < 0.05$; ** indicates $p < 0.005$; **** indicates $p < 0.0001$.

dissociated 14 days after bleomycin, fixed, permeabilized, stained with A647-conjugated antibodies against α SMA, and analyzed via flow cytometry. Compared with controls, *Col1α2-CreER*; *TCKO* mice had fewer bleomycin-induced α SMA⁺ cells (Fig. 6G), indicating decreased numbers of myofibroblasts in mice lacking mesenchymal *Fgfrs-1*, *-2*, and *-3*.

To determine whether bleomycin-induced expression of collagen and other pro-fibrotic genes were altered in *Col1α2-CreER*; *TCKO* mice, whole lung mRNA was collected 21 days after bleomycin treatment. Quantitative RT-PCR analysis revealed decreased expression of collagen genes *Col1a1* and *Col3a1* in *Col1α2-CreER*; *TCKO* mice compared with *TFF* controls (Fig. 7, A and B). No significant difference in *Col1a2* was measured between bleomycin-treated control and *TCKO* mice, although control mice, but not *TCKO* mice, demonstrated a significant increase in *Col1a2* expression in response to bleomycin compared with PBS treatment (Fig. 7C). *Col1α2-CreER*; *TCKO* mice had decreased bleomycin-induced expression of several pro-fibrotic genes compared with controls, including *Ctgf*, *Lox*, and *Serpine-1a* (*Pai1*) (Fig. 7, D–F). There was no significant difference in expression of *Postn*, IL-6, vimentin, or fibronectin in bleomycin-treated *Col1α2-CreER*; *TCKO* mice compared with *Fgfr1/2/3 TFF* controls (Fig. 7, G and H, and data not shown).

Reduced collagen expression in fibroblasts lacking *Fgfrs*

We then tested whether there was cell-autonomous FGFR-dependent gene expression in lung mesenchyme following

bleomycin treatment. *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* and *Col1α2-CreER*; *ROSA26^{mTmG/+}* mice were administered intratracheal bleomycin, and lungs were dissociated for cell sorting 21 days post-bleomycin. GFP⁺ cells were sorted directly into RNA lysis buffer, and analyzed by qRT-PCR. Freshly sorted GFP⁺ cells from bleomycin-treated *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* mice have decreased *Col1a1* expression compared with *Col1α2-CreER*; *ROSA26^{mTmG/+}* controls (Fig. 8A), but unchanged *Col3a1*, *Col1a2*, and *Ctgf* expression (Fig. 8, B–D). GFP⁺ *TCKO* cells had decreased *Col3a1* expression following PBS treatment (Fig. 8B), and no significant change in *Lox* and *Pai1* expression (Fig. 8, E and F). GFP⁺ cells from control mice, but not *TCKO* mice, demonstrated a significant increase in *Lox* and *Pai1* expression in response to bleomycin compared with PBS treatment (Fig. 8, E and F). Additionally, GFP⁺ cells from *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* mice had significantly decreased bleomycin-induced *Postn* expression (Fig. 8G), and an attenuated reduction in *Pdgfra* in response to bleomycin (Fig. 8H).

Freshly sorted GFP⁺ cells from *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* and *Col1α2-CreER*; *ROSA26^{mTmG/+}* mice were also cultured, serum-starved, and treated with 2 ng/ml of TGF- β 1 for 48 h. GFP⁺ *TCKO* mesenchymal cells show reduced *Col1a1* expression compared with controls in response to TGF- β 1 (Fig. 9A), but unchanged phosphorylation of Smad2 (Fig. 9, B and C).

Mesenchyme-specific FGFR KO mice demonstrate decreased enrichment of the *Col1α2+* lineage in fibrotic areas

We observed fewer GFP⁺ cells in bleomycin-treated *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* lungs, as seen in Fig. 5, G–J, and hypothesized that the mechanism by which *Col1α2-CreER*; *TCKO* mice have decreased fibrosis and myofibroblasts after bleomycin injury is through impaired lineage expansion of *Col1a2+* mesenchyme into areas of fibrosis. To test this, *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* and *Col1α2-CreER*; *ROSA26^{mTmG/+}* control mice were provided a 4-week washout period post-tamoxifen, and administered intratracheal PBS or bleomycin. The *Col1a2+* lineage was initially evaluated using GFP immunofluorescence and co-localization with α SMA 21 days post-bleomycin (Fig. 10, A–H). In bleomycin-treated *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* mice, there were fewer GFP⁺ cells in fibrotic areas, and fewer α SMA⁺ cells throughout the lungs compared with controls (Fig. 10, A–E, also see Figs. 5, C–J, and 6G). To better determine α SMA⁺ expression in GFP⁺ *TCKO* mesenchymal cells, dissociated lungs from bleomycin-treated *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* and *Col1α2-CreER*; *ROSA26^{mTmG/+}* mice were stained with A647-conjugated anti- α SMA antibodies and analyzed by flow cytometry. PBS-treated *TCKO* mice had unaltered abundance of α SMA⁺ cells in both GFP⁺ and GFP[–] populations (Fig. 10, I and J). Following bleomycin treatment, there were fewer α SMA⁺, GFP[–] cells in *TCKO* mice but unchanged α SMA⁺, GFP⁺ cells in *TCKO* lungs compared with controls (Fig. 10, I and J), suggesting an indirect effect of FGFR signaling on α SMA expression following bleomycin.

To quantify the abundance of GFP-labeled mesenchymal cells in *Col1α2-CreER*; *TCKO*; *ROSA26^{mTmG/+}* mouse lungs




Figure 5. Decreased ERK1/2 phosphorylation in *Col1α2-CreER; TCKO* mice. *Col1α2-CreER; TCKO* and control *Fgfr1/2/3* TFF mice were administered a single dose of intratracheal bleomycin (1.2 units/kg) or PBS. Total protein was isolated from whole lungs 21 days post-bleomycin, and analyzed by Western blotting for phosphorylated ERK1/2, total ERK1/2, and tubulin (A). Densitometric analysis was performed on $n = 3-4$ replicates, and pERK1/2:total ERK1/2 ratios were normalized to tubulin and expressed as fold-change from PBS-treated *Fgfr1/2/3* TFF control mice (B). * indicates $p < 0.05$. C–J, lungs from 21 day post-bleomycin *Col1α2-CreER; TCKO; ROSA26^{mtmG/+}* and *Col1α2-CreER; ROSA26^{mtmG/+}* mice were inflation-fixed with 4% PFA (20 cm of H₂O pressure), and frozen sections were stained for phosphorylated ERK1/2. C and G, confocal images were obtained at $\times 40$ magnification for GFP (green), ERK1/2 (red), and DAPI (blue). Higher magnifications of areas indicated by dotted lines are shown for control (D–F) and TCKO (H–J) mice. Arrows indicate phospho-ERK1/2 positive cells. ns, not significant.

compared with controls, GFP immunohistochemistry in areas with similar amounts of fibrosis were compared. The *Col1α2*+ lineage had decreased enrichment in areas of fibrosis following bleomycin in TCKO mice (Fig. 11, A–C). Additionally, the overall abundance of GFP+ cells, as a percentage of total lung single cells detected using flow cytometry, was decreased in TCKO mice compared with controls (Fig. 11D). The overall abundance of GFP+ cells did not significantly increase following bleomycin compared with PBS controls (not shown), consistent with prior reports (24). We then assessed proliferation in response to bleomycin in TCKO mice by EdU labeling prior to lung collection, enzymatic dissociation, and cell sorting. *Col1α2-CreER; TCKO* mice have decreased numbers of EdU+ cells within the overall single cell population and in the Lin-neg mesenchymal population (Fig. 11, E and F), demonstrating

decreased proliferation in mesenchyme after bleomycin-induced injury. We then measured growth in cultures of Lin-neg, GFP+ cells isolated from *Col1α2-CreER; TCKO; ROSA26^{mtmG/+}* and control *Col1α2-CreER; ROSA26^{mtmG/+}* mice 21 days after bleomycin. Compared with controls, *Col1α2-CreER; TCKO; ROSA26^{mtmG/+}* mesenchymal cells demonstrate decreased growth over a 9-day period (Fig. 11G). This demonstrates that FGFR signaling is required for proliferation and expansion of a pre-existing mesenchymal population that contributes to bleomycin-induced pulmonary fibrosis.

Discussion

In this report, we demonstrate that FGFRs-1, -2, and -3 in *Col1α2*+ lung mesenchyme and fibroblasts are required for bleomycin-induced pulmonary fibrosis and collagen produc-

Fibroblast-specific FGFR signaling in pulmonary fibrosis




Figure 6. Decreased bleomycin-induced fibrosis in *Col1α2-CreER; TCKO* mice. *Col1α2-CreER; TCKO* and control *Fgfr1/2/3 TFF* mice were administered a single dose of intratracheal bleomycin (1.2 units/kg) or PBS. Mice were monitored for weight loss (A) and survival (B) over a 21-day period. * indicates $p < 0.05$ via two-way analysis of variance. Survival was analyzed using Kaplan-Meier survival analysis, * indicates $p < 0.05$. Mouse lungs were collected 21 days post-bleomycin for Ashcroft fibrosis scoring (C), H&E staining (D), quantitative hydroxyproline analysis (E), and Masson's trichrome staining (F). To measure the number of α SMA+ myofibroblasts, bleomycin-treated *Col1α2-CreER; TCKO* and control *Col1α2-CreER; TCKO* mouse lungs were collected after 14 days, enzymatically dissociated, fixed, permeabilized, stained for α SMA, and analyzed by flow cytometry (G). * indicates $p < 0.05$; ** indicates $p < 0.005$. ns, not significant.

tion. Furthermore, we showed that FGFR signaling is required for bleomycin-induced collagen expression in freshly isolated fibroblasts. Additionally, intact FGFR signaling in lung mesenchyme is required for lineage-specific expansion of fibrotic tissue in response to bleomycin.

FGF signaling has been implicated in the pathogenesis of pulmonary fibrosis, as non-selective inhibition of receptor tyrosine kinases (7) and nonspecific inhibition of FGF receptors (9, 25) decrease bleomycin-induced pulmonary fibrosis in rodents.

FGFR signaling (in addition to VEGFR and PDGFR) is inhibited by Nintedanib, which decreases the rate of decline in lung function in IPF patients (3, 4). The mechanism by which inhibition of multiple receptor tyrosine kinases decreases the progression of pulmonary fibrosis remains unclear. Nintedanib reduces fibronectin and collagen expression, induces autophagy, and inhibits TGF β signaling in IPF lung fibroblasts (26). Our data demonstrates that there is a cell-autonomous role for FGFR signaling in pulmonary fibrosis that promotes expansion of




Figure 7. Decreased pro-fibrotic gene expression in *Col1a2-CreER; TCKO* mice after bleomycin treatment. *Col1a2-CreER; TCKO* and control *Fgfr1/2/3 TFF* mice were administered a single dose of intratracheal bleomycin (1.2 units/kg) or PBS and mouse lungs were collected 21 days post-bleomycin for whole lung RNA. Quantitative RT-PCR was performed for *Col1α1* (A), *Col3α1* (B), *Col1α2* (C), *Ctgf* (D), *Lox* (E), *Pai1* (F), *Postn* (G), and *IL-6* (H). Data were normalized to *Gapdh* and expressed as fold-change from PBS-treated *Fgfr1/2/3 TFF* controls. * indicates $p < 0.05$; ** indicates $p < 0.005$. ns, not significant.

lung fibroblasts into injured areas within the lung. A recent report by MacKenzie *et al.* (11) described increased migration of fibroblasts in response to FGF1, further supporting our findings that FGF signaling is required for fibroblast expansion within fibrotic areas.

Our studies use bleomycin as a model agent to induce fibrosis. One percent of patients treated with bleomycin develop pulmonary fibrosis (27). In mice, bleomycin causes alveolar epithelial injury, inflammation, and fibroblast proliferation and differentiation into myofibroblasts. Although bleomycin does not cause lesions characteristic for IPF (fibroblastic foci and honeycombing) in the mouse lung, bleomycin remains a well established and useful model to study underlying mechanisms of alveolar epithelial cell injury and subsequent fibroblast activation and fibrosis (27, 28, 30, 31).

Col1a2-CreER mice have been used previously to inactivate genes in lung mesenchyme that are important for the development of pulmonary fibrosis, including *Tert* (32), smoothed (33), *TgfbR1* (19), *Notch1* (34), and *CEBPβ* (20). It is important to note that this allele targets multiple mesenchymal populations, and it is difficult to assess which population within the

Col1a2+ lineage directly contributes to fibrotic areas in the lung. Furthermore, we have found that cultured lung fibroblasts generated from enzymatically dissociated *Col1a2-CreER; ROSA26^{mTmG/+}* whole lungs, without enrichment for GFP+ cells via cell sorting, results in a heterogeneous population of cells, with only 50–60% of the cells being GFP+ (not shown). Incorporating the *ROSA26^{mTmG}* Cre reporter allele with the *Col1a2-CreER* allele allows for direct analysis of lineage labeled and genetically manipulated mesenchymal cells both *in vivo* and *in vitro*.

This study underscores the importance of studying fibroblasts *in vivo*, as we have found that *Fgfr* expression changes significantly once lung fibroblasts are placed in culture, even after a single passage. We demonstrate significant expression of all *Fgfrs* in freshly isolated lung mesenchyme; however, only *Fgfr1* is expressed when isolated fibroblasts are cultured. Low levels of *Fgfr3* and *Fgfr4* expression in cultured lung fibroblasts has previously been reported (35). *FGFRs* 1–4 were also found to be expressed in myofibroblasts of fibroblastic foci in human IPF lung biopsies (11). The mechanism(s) responsible for this change in *Fgfr* expression is not known; however, altered cellu-

Fibroblast-specific FGFR signaling in pulmonary fibrosis




Figure 8. Decreased collagen expression in purified *Col1α2-CreER; TCKO* lung mesenchymal cells. *Col1α2-CreER; TCKO; ROSA26^{mTmG/+}* and control *Col1α2-CreER; ROSA26^{mTmG/+}* mice were treated with a single dose of intratracheal bleomycin (1.2 units/kg) or PBS. A, lungs were harvested and dissociated 21 days post-bleomycin, and GFP+ cells were collected via cell sorting directly into RNA lysis buffer. RNA purified from GFP+ cells was analyzed by quantitative RT-PCR for *Col1α1* (A), *Col3α1* (B), *Col1α2* (C), *Ctgf* (D), *Lox* (E), *Pai1* (F), *Postn* (G), and *Pdgfra* (H). Data were normalized to *Gapdh* and expressed as fold-change from PBS-treated controls. * indicates $p < 0.05$; ** indicates $p < 0.005$; *** indicates $p < 0.001$; **** indicates $p < 0.0001$. ns, not significant.

lar phenotypes and gene expression as a result of culture conditions, including substrate stiffness and coating of culture dishes have been well described (36).

Simultaneous deletion of multiple FGF receptors was performed due to 1) overlapping receptor specificity of many FGFs to FGFRs 1–3, including FGF1, FGF2, and FGF9 (22), and 2) simultaneous expression of multiple *Fgfrs* in lung mesenchyme *in vivo* (Fig. 2). Although mesenchymal cells with deletion of FGFRs 1–3 demonstrate a functional deficiency of FGF signaling, it remains possible that FGFR4 could further contribute to lung fibroblast pathophysiology. Targeting *Fgfr4* in lung mesenchyme and fibroblasts is an area of future study. Additionally, the individual roles of FGFR1, FGFR2, and FGFR3 in lung mesenchyme following injury and in the development of pulmonary fibrosis is not known, and future studies will be needed to determine the relative contribution of individual FGFRs. Mice expressing a soluble dominant-negative FGFR2 in late gestation, but not postnatally, causes airspace enlargement and

emphysema (37). FGFR3 may represent a significant FGFR in adult lung pathophysiology. FGFR3 and FGFR4 have been shown to be critical for early postnatal alveologenesis (35, 38), and mice with combined deficiencies of *Fgfr3* and *Fgfr4* have excessive elastic fiber deposition; however, their importance in lung injury and pulmonary fibrosis are not well described. Recent reports have also implicated FGFR3 in the pathogenesis of lung cancer (39–41).

Although mesenchyme-specific FGFR signaling is important for bleomycin-induced pulmonary fibrosis, the endogenous FGF ligand(s) that mediate this pathology remains unclear. FGF1 and FGF2 are capable of activating most FGF receptors, including FGFR1, the mesenchyme-specific FGFR2c splice variant, and FGFR3 (10, 22). Inhibition of FGFR2c ligands by expressing a soluble FGFR2c ectodomain (25) decreases bleomycin-induced fibrosis, and whereas this implicates FGF signaling in the pathogenesis of fibrosis, it does not point to a single ligand, as FGFR2c interacts with multiple ligands, includ-




Figure 9. Decreased collagen expression in response to TGF- β 1 in cultured *Col1 α 2-CreER; TCKO* lung mesenchymal cells. GFP⁺ cells from uninjured *Col1 α 2-CreER; TCKO; ROSA26^{mTmG/+}* and control *Col1 α 2-CreER; ROSA26^{mTmG/+}* mice were collected by cell sorting and grown in culture. After 2 passages, cells were serum-starved overnight and treated with TGF- β 1 (2 ng/ml). RNA was collected from cells 48 h after treatment, and analyzed by quantitative RT-PCR for *Col1 α 1* (A). Data were normalized to *Gapdh* and expressed as fold-change from PBS-treated controls. B and C, total protein, collected after 1 h of treatment, was analyzed by Western blot analysis for phosphorylated Smad2 and tubulin. Densitometric analysis was performed on $n = 6$ replicates, and pSmad2 was normalized to tubulin and expressed as fold-change from control (C). * indicates $p < 0.05$; ** indicates $p < 0.005$. ns, not significant.

ing FGF1, FGF2, FGF8, FGF9, and FGF18 (10). We recently reported that *Fgf2* knock-out mice have preserved fibrosis in response to bleomycin (42), which suggests that other FGF ligands are either required for bleomycin-induced fibrosis or compensate for the absence of FGF2. A combined knock-out of FGF1 and FGF2 has decreased carbon tetrachloride-induced hepatic fibrosis (43), but the response of these mice to intratracheal bleomycin is not known. FGF1 is increased in IPF lungs, and is capable of increasing fibroblast migration *in vitro* (11). FGF9 and FGF18 are increased in IPF, stimulate fibroblast migration, and decrease fibroblast apoptosis (44, 45). Inhibition of endogenous FGFR2b ligands (FGF7 and FGF10) does not alter bleomycin-induced pulmonary fibrosis (46), suggesting that these ligands are not essential for fibrosis. As the FGF ligand(s) critical for bleomycin-induced fibrosis remain unclear, further examination of the critical FGFRs are likely to provide insight to the ligands involved, as FGF-FGFR specificity is well described (22). Furthermore, pharmacologic targeting of FGFRs may be more efficacious than targeting specific FGF ligands, particularly given overlap in ligand-receptor interactions and as multiple FGF ligands are likely involved in fibrosis. Furthermore, targeting FGFR tyrosine kinases may potentially be done in a cell-type specific manner. Continued studies using *Col1 α 2-CreER* to inactivate individual *Fgfs* will determine which receptor is most critical for bleomycin-induced pulmonary fibrosis, and will allow for improved therapeutics targeted against fibroblasts contributing to fibrotic diseases.

FGF signaling in other cell types may also contribute to the development of fibrosis. A recent report suggested that endothelial FGFR1 signaling is required for hepatic fibrosis (47), as endothelial-specific deletion of FGFR1 lessened liver fibrosis in response to

bile duct ligation. The role of endothelium and angiogenesis, and in particular endothelial-specific FGF signaling, in pulmonary fibrosis is not well understood (48) and warrants further study.

We show that inactivation of FGFRs in mesenchymal cells decreases collagen expression in response to bleomycin and TGF- β 1. This appears to be a cell-autonomous effect, as collagen expression is altered in isolated Cre-expressing mesenchymal cells following bleomycin treatment. These data also support prior reports where FGF2 signaling is required for TGF- β 1 induced collagen expression in lung fibroblasts (14, 15, 17). Other studies have demonstrated an inhibitory effect of FGFRs on pulmonary fibrosis and TGF- β 1-induced myofibroblast differentiation (44, 45, 49–52); however, those studies use exogenous or overexpressed FGF ligands and no study to date has demonstrated an inhibitory role of endogenous FGF ligands on pulmonary fibrosis *in vivo*.

Our data also suggests that deletion of FGF receptors leads to a cell non-autonomous effect on mesenchymal cells that are not targeted by *Col1 α 2-CreER*. Deletion of FGFRs in the *Col1 α 2+* lineage leads to alteration in the abundance of GFP-negative, α SMA⁺ cells as well as expression of *Col3a1*, *Ctgf*, *Lox*, and *Pai1* in whole lung, but not GFP⁺ (*Col1 α 2+* lineage) mesenchymal cells. Future studies will investigate the factor(s) involved in this interaction, as well as the cell types involved. It should be noted that our experiments inactivated FGFRs prior to lung injury, and future studies will also address whether inactivation of FGFRs in the *Col1 α 2+* lineage post-bleomycin has similar cell autonomous and non-autonomous effects. Additional studies are needed to determine the mechanistic role of FGFRs in multiple phases of fibroblast activation following injury and in response to pro-fibrotic growth factors such as TGF- β 1, including migration, metabolism, differentiation into myofibroblasts, and recovery from injury.

In summary, this study provides direct evidence that deletion of FGFRs in lung mesenchyme in adult mice decreases pulmonary fibrosis, reduces fibroblast-specific collagen expression, and decreases fibroblast enrichment in fibrotic areas in response to bleomycin. This study provides a mechanistic rationale for the use of FGF inhibitors to slow the progression of pulmonary fibrosis. Improved understanding of the contributions of FGF and other growth factor pathways to the development of fibrosis remains important, and future studies are needed to determine fibroblast-specific, FGFR-dependent pathways amenable to therapeutic intervention for improved therapy in IPF and other fibrotic diseases.

Experimental procedures

Animal care and use

Mice were housed in a pathogen-free barrier facility and handled in accordance with standard protocols, animal welfare regulations, and the NIH guide for the Care and Use of Laboratory Animals. All procedures complied with the standards for the care and use of laboratory animals as stated in the *Guide or the Care and Use of Laboratory Animals* (NIH publication No. 85-23, revised 1996), and all protocols were approved by the Animal Studies Committee at Washington University School of Medicine and at the University of Chicago.

Fibroblast-specific FGFR signaling in pulmonary fibrosis




Figure 10. Altered α SMA expression in *Col1α2-CreER; TCKO* mice following bleomycin treatment. *Col1α2-CreER; TCKO; ROSA26^{mTmG/+}* and control *Col1α2-CreER; ROSA26^{mTmG/+}* mice were administered a single dose of intratracheal bleomycin (1.2 units/kg) or PBS. (A–H) Sections from lungs collected 21 days post-bleomycin were stained for α SMA and GFP. A and E, confocal images were obtained at $\times 20$ magnification for GFP (green), α SMA (red), and DAPI (blue). Higher magnifications of areas indicated by dotted lines are shown for control (B–D) and TCKO (F–H) mice. Arrows indicate α SMA+ cells. I and J, lungs were dissociated, fixed, permeabilized, stained with BV421-conjugated antibodies against CD45, CD31, and EpAM (Lin) as well as A647-conjugated anti- α SMA antibodies, and analyzed by flow cytometry. Lin-negative cells were analyzed for expression of GFP and α SMA, and the percentage of Lin-negative cells that are α SMA+, GFP- (I) and α SMA+, GFP+ (J) are shown. * indicates $p < 0.05$. ns, not significant.

Experiments were carried out using *Col1α2-CreER* mice (53) mated to mice containing floxed alleles for FGFRs 1, 2, and 3 (*Fgfr1^{f/f}; Fgfr2^{f/f}; Fgfr3^{f/f}*) (54, 55) referred to as TFF. To maintain this line of mice, male *Col1α2-CreER; Fgfr1^{f/f}; Fgfr2^{f/f}; Fgfr3^{f/f}* mice were mated to female *Fgfr1^{f/f}; Fgfr2^{f/f}; Fgfr3^{f/f}; ROSA26^{mTmG/mTmG}* mice. Cre-negative TFF littermates and Cre+ mice without floxed *Fgfr* alleles were used as controls. Mice containing the Cre reporter allele and the *ROSA26^{mTmG}* allele allow for identification of targeted fibroblasts after treatment with tamoxifen. After treatment with tamoxifen, these mice are referred to as triple conditional knock-out mice (*Col1α2-CreER; TCKO*). All mice were maintained in a C57BL/6j;129X1 mixed background.

Bleomycin-induced lung fibrosis

Mice were fed tamoxifen chow for 14 days starting at 3 weeks of age, and subsequently fed regular chow. Adult mice between

8 and 10 weeks of age were sedated, orally intubated, and administered a single dose of intratracheal bleomycin (1.2 units/kg) (Sigma) in sterile phosphate-buffered saline (PBS) or PBS alone. Mice were monitored daily and weight was measured twice weekly. Mice with $>25\%$ weight loss or significant respiratory distress were humanely euthanized and treated as a death. At various times after treatment, mice were euthanized with an overdose of a mixture containing ketamine and xylazine, and exsanguinated by cutting the abdominal aorta. Lungs were then slowly perfused with 5 ml of PBS via the right ventricle. The trachea was dissected and cannulated, and lungs were fixed via intra-tracheal inflation with 10% phosphate-buffered formalin at a pressure of 20 cm H₂O for 10 min, followed by immersion in fresh fixative for 24 h at room temperature. Samples were then dehydrated in ethanol and xylene, embedded in paraffin, cut in 5- μ m sections, and stained with hematoxylin and eosin (H&E) and Masson's trichrome.




Figure 11. Decreased proliferation and enrichment of Col1α2+ lineage in fibrotic areas in bleomycin-treated Col1α2-CreER; TCKO mice. Col1α2-CreER; TCKO; ROSA26^{mTmG/+} and control Col1α2-CreER; ROSA26^{mTmG/+} mice were administered a single dose of intratracheal bleomycin (1.2 units/kg) and lungs were collected 21 days post-bleomycin. Immunohistochemistry for GFP was performed (A and B) and the percentage of total fibrotic areas that were GFP+ was analyzed using ImageJ (C). Whole lungs were dissociated and the percentage of total live single cells that were GFP+ following bleomycin treatment were analyzed by flow cytometry (D). Proliferation was measured by injecting mice with EdU (50 mg/kg i.p.) prior to collection, and dissociated lungs were stained for CD45, CD31, and EpCam (Lin), fixed, permeabilized, and then stained for EdU incorporation. Stained cells were measured by flow cytometry, and EdU incorporation within all single cells (D) or Lin-negative cells (E) was analyzed. GFP+ cells from bleomycin-treated Col1α2-CreER; TCKO; ROSA26^{mTmG/+} and control Col1α2-CreER; ROSA26^{mTmG/+} mice were sorted into 96-well plates (2,000 cells/well) and cultured for 48 h, 5 days, 7 days, and 9 days prior to measurement of total cellular DNA using a CyQuant assay (F). * indicates $p < 0.05$; ** indicates $p < 0.005$. ns, not significant.

Fibrosis scoring

Ashcroft scoring was performed as described previously (29). Briefly, all lobes were sectioned on a single slide, and 20 non-overlapping trichrome-stained $\times 10$ fields were scored per sample, and the average score of all fields indicates the Ashcroft score of a single sample. The scoring scale was as follows: 0 = no abnormalities, 1 = slight thickening of alveolar membranes, 2 = small areas of fibrosis (<10%), 3 = 10–20% fibrotic area, 4 = 20–40% fibrotic area, 5 = 40–60% fibrosis, 6 = 60–80% fibrosis, 7 = >80% fibrosis, and 8 = complete fibrosis.

Whole slide scanning

Digital scanning of whole slides was performed using a Nanozoomer 2.0 HT digital slide scanner (Hamamatsu, Bridge-

water, NJ), available through the Washington University Hope Center Alafi Neuroimaging Lab (NIH Shared Instrumentation Grant (S10 RR027552)), or using an Aperio ScanScope XT through the University of Chicago Human Tissue Resource Center.

Hydroxyproline assay

Left lung samples were transferred into glass tubes and hydrolyzed with 200 μ l of 6 N HCl at 110 °C for 48 h. The hydrolyzed samples were evaporated to dryness to remove excess HCl, reconstituted with 400 μ l of H₂O, and filtered in 1.5-ml centrifuge tubes equipped with a 0.45- μ m semipermeable membrane filter. Samples were added to a 96-well microplate, chloramine T solution was added and the plate incubated at

Fibroblast-specific FGFR signaling in pulmonary fibrosis

room temperature for 20 min. 100 μ l of Erlich's reagent was added to each well and the plate was incubated at 65 °C for 18 min. This method gives an orange-red color that is linear up to 6 μ g of hydroxyproline. A_{550} nm was obtained, and compared with a hydroxyproline standard curve.

Immunohistochemistry and immunofluorescence

Five- μ m sections were prepared from paraffin-embedded tissues, and deparaffinized with xylene. Endogenous peroxidase was inhibited by incubation with 3% H₂O₂ in methanol, and sections were then re-hydrated. Antigen retrieval was performed using a pressure cooker and citrate buffer (pH 6.0). Samples were incubated in PBS, and blocked in PBS + 0.2% Triton X-100 + 0.1% BSA + 5% serum. Primary antibodies for GFP (GFP-1010, Aves Inc, Tigard, OR), α SMA (M0851, Dako North America, Carpinteria, CA), PDGFR α (sc-338, Santa Cruz Biotechnology, Dallas, TX), pro-SPC (ab90716, Abcam, Cambridge, UK), s100a4 (ab27957, Abcam), and periostin (ab14041, Abcam) were added to blocking buffer and slides were incubated overnight at 4 °C. Slides were washed with PBS, and for immunohistochemistry studies a biotin-conjugated secondary antibody was added, followed by streptavidin-HRP. Colorimetric reaction was performed using DAB staining (Vector Labs, Burlingame, CA), and sections were counterstained with hematoxylin. Immunofluorescent imaging was performed using a Zeiss Apotome or a Marianas Tokogawa spinning disk confocal microscope, and image processing was performed using Zeiss AxioPlan and ImageJ (NIH, Bethesda, MD).

Quantification of GFP immunohistochemistry

Paraffin sections from PBS- and bleomycin-treated mice were deparaffinized and stained with an anti-GFP antibody and colorimetric reaction was performed using DAB staining. 10–15 non-overlapping \times 10 fields containing areas of tissue fibrosis were analyzed using ImageJ software to determine the percentage of total fibrotic area that was stained for GFP.

RNA isolation and quantitative real-time PCR

RNA was isolated from whole lungs or whole left lungs via homogenization in TRIzol, and subsequent purification using RNeasy spin columns (74104, Qiagen, Valencia, CA), with on-column DNA digest, per the manufacturer's instructions. RNA concentration was determined utilizing a Nanodrop spectrophotometer. cDNA was made using the Bio-Rad iScript Reverse Transcription Supermix for RT-qPCR kit (170-8841, Bio-Rad). Quantitative RT-PCR was performed on an Applied Biosystems StepOne thermocycler using ABI TaqMan[®] Fast Advanced Master Mix (number 4444557, Applied Biosystems, Foster City, CA) and TaqMan[®] gene expression assays. All samples were normalized to *Gapdh* and then scaled relative to controls using the standard $\Delta\Delta C_t$ method. Data are reported as ΔC_t or fold-change relative to wild type PBS-treated mice.

Protein extraction and Western blotting

Protein was extracted from whole left lung or cultured fibroblasts via homogenization in RIPA buffer with freshly added 2% Protease Inhibitor Mixture (P8340, Sigma) and Phosphatase

Inhibitor Mixture I and II (P2850 and P5726, Sigma). Protein concentration was determined utilizing a Pierce BCA assay kit (23225, Thermo Scientific, Rockford, IL). Total protein (50–100 μ g) was separated on 4–12% polyacrylamide gels (Bio-Rad) and transferred to PVDF membranes using a Trans-Blot Turbo transfer system (Bio-Rad). Membranes were blocked for 1 h at room temperature with gentle shaking in TBST (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween 20) containing 5% nonfat milk or 5% BSA, and then probed with primary antibodies against phospho-ERK1/2 (number 4376, Cell Signaling Technology, Danvers, MA), ERK1/2 (Cell Signaling number 9102), tubulin (Abcam number ab6046), and phospho-Smad2 (Cell Signaling number 3101) overnight at 4 °C. After three rinses in TBST, membranes were incubated for 1 h at room temperature in horseradish peroxidase-linked secondary antibodies in TBST with 5% nonfat milk, rinsed again in TBST, and developed using SuperSignal West Femto Substrate (34096, Thermo Scientific). Protein bands were quantified using Image Lab (Bio-Rad), normalized to tubulin, and scaled relative to control samples set at a value of 1.

Flow cytometry and cell sorting

Mice were euthanized with an overdose of a mixture containing ketamine and xylazine, and exsanguinated by cutting the abdominal aorta. Lungs were then slowly perfused with 5 ml of cold PBS via the right ventricle. The trachea was dissected and cannulated, and lungs were inflated with DMEM digest media containing LiberaseTM (Roche Diagnostics), hyaluronidase (Sigma), elastase (Worthington Biochemical, Lakewood, NJ), and DNase (Sigma). Inflated lungs were transferred to digest media and placed on ice until all mice were dissected. Lungs were then minced with razor blades and incubated in digest medium at 37 °C for 30 min with agitation. Digest enzymes were inactivated with DMEM with 10% FBS, and samples were filtered with a 100- μ m strainer. Red blood cells were then lysed with ACK buffer (Thermo Scientific) and cells were resuspended in FACS buffer (PBS + 3% FBS + 1 mM EDTA). Cells were stained with BV-421-conjugated antibodies against CD45, CD31, and CD326 (EpCAM) (BioLegend, San Diego, CA). GFP+ cells were sorted using a Sony Synergy (Washington University) or FACSaria II (University of Chicago), using a 100- μ m diameter nozzle. For culture, cells were sorted directly into complete media containing 10% FBS. For RNA isolation, between 50,000 and 100,000 cells were sorted directly into RLT lysis buffer with β -mercaptoethanol, and RNA was purified using an RNeasy Plus Micro Kit (Qiagen).

For detection of α SMA+ myofibroblasts via flow cytometry, dissociated cells were stained with BV-421-conjugated antibodies against CD45, CD31, and CD326 (EpCAM), and subsequently fixed with 4% paraformaldehyde. Fixed cells were washed with PBS + 1% BSA + 0.1% sodium azide and permeabilized using the BD cytofix/cytoperm kit (BD Biosciences). Fixed cells were stained with A647-conjugated anti- α SMA antibodies (number NBP2–34522AF647, Novus Biologicals, Littleton, CO), washed, and measured using a BD LSR II flow cytometer. Data were analyzed using FlowJo software.

Lung fibroblast isolation and culture

GFP-labeled cells were sorted directly into culture media, and subsequently cultured on collagen-coated plates in DMEM with 10% FBS, penicillin/streptomycin, fungizone, L-glutamine, and HEPES. Cells were grown in a humidified incubator at 37 °C with 5% CO₂. Media was replaced every other day, and cultured fibroblasts were used for experiments between passages 2 and 5.

In vivo proliferation assay

Prior to collection, mice were given an intraperitoneal injection of EdU (50 mg/kg, Thermo Fisher). Mouse lungs were enzymatically dissociated as described above, and cells were stained with BV-421-conjugated antibodies against CD45, CD31, and CD326 (EpCAM) (BioLegend). Cells were then fixed, permeabilized, and stained for EdU using the Click-iT EdU assay (Thermo Fisher) according to the manufacturer's protocol. Flow cytometry was performed using a BD LSR II cytometer, and data analyzed using FlowJo.

In vitro proliferation assay

Mouse lungs were dissociated and stained with BV-421-conjugated antibodies against CD45, CD31, and CD326 (EpCAM) (BioLegend) as described, dead cells were excluded using 7-aminoactinomycin staining, and 2000 GFP+ cells were directly sorted into individual wells of 96-well collagen-coated plates containing complete media using a FACSAria II sorter. Cells were grown as described above. At specified times, plates were washed with PBS and placed at -80 °C. DNA content was measured using a CyQuant assay per manufacturer protocol.

Statistical analysis

Significant differences in mean values were calculated using paired Student's *t* tests or one-way analysis of variance. Survival analysis was performed using Kaplan-Meier analysis. A *p* value of less than 0.05 was considered to be significant.

Author contributions—R. D. G. participated in the design of the study, performed all animal experiments and most molecular analyses, performed statistical analysis, and drafted the manuscript. L. L. participated in animal care and performed quantitative RT-PCR assays. C. S. participated in animal experiments and in the design of the study. S. J. D. performed immunohistochemistry and immunofluorescence and participated in animal experiments. H. Y. K. performed quantitative RT-PCR assays and participated in animal experiments. L. C. developed FGFR3 flox mice used in this study. D. M. O. participated in the design of the study, and helped draft the manuscript. All authors read and approved the final manuscript.

References

- King, T. E., Jr., Pardo, A., and Selman, M. (2011) Idiopathic pulmonary fibrosis. *Lancet* **378**, 1949–1961
- Blackwell, T. S., Tager, A. M., Borok, Z., Moore, B. B., Schwartz, D. A., Anstrom, K. J., Bar-Joseph, Z., Bitterman, P., Blackburn, M. R., Bradford, W., Brown, K. K., Chapman, H. A., Collard, H. R., Cosgrove, G. P., Detering, R., et al. (2014) Future directions in idiopathic pulmonary fibrosis research: an NHLBI workshop report. *Am. J. Respir. Crit. Care Med.* **189**, 214–222

- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., et al. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N. Engl. J. Med.* **370**, 2071–2082
- King, T. E., Jr., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glasspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., et al. (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N. Engl. J. Med.* **370**, 2083–2092
- Schaefer, C. J., Ruhmund, D. W., Pan, L., Seiwert, S. D., and Kossen, K. (2011) Antifibrotic activities of pirfenidone in animal models. *Eur. Respir. Rev.* **20**, 85–97
- Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., and Arimura, A. (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. *Eur. J. Pharmacol.* **590**, 400–408
- Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., and Ryffel, B. (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. *J. Pharmacol. Exp. Ther.* **349**, 209–220
- Chaudhary, N. I., Roth, G. J., Hilberg, F., Müller-Quernheim, J., Prasse, A., Zissel, G., Schnapp, A., and Park, J. E. (2007) Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. *Eur. Respir. J.* **29**, 976–985
- Yu, Z. H., Wang, D. D., Zhou, Z. Y., He, S. L., Chen, A. A., and Wang, J. (2012) Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice. *Biol. Pharm. Bull.* **35**, 731–736
- Zhang, X., Ibrahim, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., and Ornitz, D. M. (2006) Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. *J. Biol. Chem.* **281**, 15694–15700
- MacKenzie, B., Korfei, M., Henneke, I., Sibinska, Z., Tian, X., Hezel, S., Dilai, S., Wasnick, R., Schneider, B., Wilhelm, J., El Agha, E., Klepetko, W., Seeger, W., Schermuly, R., Günther, A., and Belluscio, S. (2015) Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. *Respir. Res.* **16**, 83
- Lin, N., Chen, S., Pan, W., Xu, L., Hu, K., and Xu, R. (2011) NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats. *Am. J. Physiol. Cell Physiol.* **301**, C469–C477
- Thannickal, V. J., Aldweib, K. D., Rajan, T., and Fanburg, B. L. (1998) Upregulated expression of fibroblast growth factor (FGF) receptors by transforming growth factor- β 1 (TGF- β 1) mediates enhanced mitogenic responses to FGFs in cultured human lung fibroblasts. *Biochem. Biophys. Res. Commun.* **251**, 437–441
- Finlay, G. A., Thannickal, V. J., Fanburg, B. L., and Paulson, K. E. (2000) Transforming growth factor- β 1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor. *J. Biol. Chem.* **275**, 27650–27656
- Khalil, N., Xu, Y. D., O'Connor, R., and Duronio, V. (2005) Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor- β 1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. *J. Biol. Chem.* **280**, 43000–43009
- Osaki, T., Yoneda, K., Tatamoto, Y., Yamamoto, T., Yokoyama, T., and Enzan, H. (2001) Peplomycin, a bleomycin derivative, induces myofibroblasts in pulmonary fibrosis. *Int. J. Exp. Pathol.* **82**, 231–241
- Xiao, L., Du, Y., Shen, Y., He, Y., Zhao, H., and Li, Z. (2012) TGF- β 1 induced fibroblast proliferation is mediated by the FGF-2/ERK pathway. *Front. Biosci.* **17**, 2667–2674
- Strutz, F., Zeisberg, M., Renziehausen, A., Raschke, B., Becker, V., van Kooten, C., and Müller, G. (2001) TGF- β 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). *Kidney Int.* **59**, 579–592
- Hoyles, R. K., Derrett-Smith, E. C., Khan, K., Shiwen, X., Howat, S. L., Wells, A. U., Abraham, D. J., and Denton, C. P. (2011) An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-

Fibroblast-specific FGFR signaling in pulmonary fibrosis

- specific deletion of high-affinity type II transforming growth factor β receptor. *Am. J. Respir. Crit. Care Med.* **183**, 249–261
20. Hu, B., Wu, Z., Nakashima, T., and Phan, S. H. (2012) Mesenchymal-specific deletion of C/EBP β suppresses pulmonary fibrosis. *Am. J. Pathol.* **180**, 2257–2267
 21. Parapuram, S. K., Thompson, K., Tsang, M., Hutchenreuther, J., Bekking, C., Liu, S., and Leask, A. (2015) Loss of PTEN expression by mouse fibroblasts results in lung fibrosis through a CCN2-dependent mechanism. *Matrix Biol.* **43**, 35–41
 22. Ornitz, D. M., and Itoh, N. (2015) The fibroblast growth factor signaling pathway. *Wiley Interdiscip. Rev. Dev. Biol.* **4**, 215–266
 23. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., and Luo, L. (2007) A global double-fluorescent Cre reporter mouse. *Genesis* **45**, 593–605
 24. Tsukui, T., Ueha, S., Abe, J., Hashimoto, S., Shichino, S., Shimaoka, T., Shand, F. H., Arakawa, Y., Oshima, K., Hattori, M., Inagaki, Y., Tomura, M., and Matsushima, K. (2013) Qualitative rather than quantitative changes are hallmarks of fibroblasts in bleomycin-induced pulmonary fibrosis. *Am. J. Pathol.* **183**, 758–773
 25. Ju, W., Zhihong, Y., Zhiyou, Z., Qin, H., Dingding, W., Li, S., Baowei, Z., Xing, W., Ying, H., and An, H. (2012) Inhibition of α -SMA by the ectodomain of FGFR2c attenuates lung fibrosis. *Mol. Med.* **18**, 992–1002
 26. Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., Antony, V. B., Zhang, J., Zmijewski, J., and Thannickal, V. J. (2016) Novel mechanisms for the antifibrotic action of nintedanib. *Am. J. Respir. Cell Mol. Biol.* **54**, 51–59
 27. Moeller, A., Ask, K., Warburton, D., Gauldie, J., and Kolb, M. (2008) The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? *Int. J. Biochem. Cell Biol.* **40**, 362–382
 28. Mouratis, M. A., and Aidinis, V. (2011) Modeling pulmonary fibrosis with bleomycin. *Curr. Opin. Pulm. Med.* **17**, 355–361
 29. Ashcroft, T., Simpson, J. M., and Timbrell, V. (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. *J. Clin. Pathol.* **41**, 467–470
 30. Matute-Bello, G., Frevert, C. W., and Martin, T. R. (2008) Animal models of acute lung injury. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **295**, L379–L399
 31. Moore, B. B., and Hogaboam, C. M. (2008) Murine models of pulmonary fibrosis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **294**, L152–L160
 32. Liu, T., Yu, H., Ding, L., Wu, Z., Gonzalez De Los Santos, F., Liu, J., Ullenbruch, M., Hu, B., Martins, V., and Phan, S. H. (2015) Conditional knock-out of telomerase reverse transcriptase in mesenchymal cells impairs mouse pulmonary fibrosis. *PLoS One* **10**, e0142547
 33. Hu, B., Liu, J., Wu, Z., Liu, T., Ullenbruch, M. R., Ding, L., Henke, C. A., Bitterman, P. B., and Phan, S. H. (2015) Reemergence of hedgehog mediates epithelial-mesenchymal crosstalk in pulmonary fibrosis. *Am. J. Respir. Cell Mol. Biol.* **52**, 418–428
 34. Hu, B., Wu, Z., Bai, D., Liu, T., Ullenbruch, M. R., and Phan, S. H. (2015) Mesenchymal deficiency of Notch1 attenuates bleomycin-induced pulmonary fibrosis. *Am. J. Pathol.* **185**, 3066–3075
 35. Srisuma, S., Bhattacharya, S., Simon, D. M., Solleti, S. K., Tyagi, S., Starcher, B., and Mariani, T. J. (2010) Fibroblast growth factor receptors control epithelial-mesenchymal interactions necessary for alveolar elastogenesis. *Am. J. Respir. Crit. Care Med.* **181**, 838–850
 36. Tschumperlin, D. J. (2015) Matrix, mesenchyme, and mechanotransduction. *Ann. Am. Thorac. Soc.* **12**, S24–S29
 37. Hokuto, I., Perl, A. K., and Whitsett, J. A. (2003) Prenatal, but not postnatal, inhibition of fibroblast growth factor receptor signaling causes emphysema. *J. Biol. Chem.* **278**, 415–421
 38. Weinstein, M., Xu, X., Ohyama, K., and Deng, C. X. (1998) FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. *Development* **125**, 3615–3623
 39. Yin, Y., Betsuyaku, T., Garbow, J. R., Miao, J., Govindan, R., and Ornitz, D. M. (2013) Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. *Cancer Res.* **73**, 5730–5741
 40. Yin, Y., Ren, X., Smith, C., Guo, Q., Malabunga, M., Guernah, I., Zhang, Y., Shen, J., Sun, H., Chehab, N., Loizos, N., Ludwig, D. L., and Ornitz, D. M. (2016) Inhibition of FGF Receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody. *Dis. Model. Mech.* **9**, 563–571
 41. Arai, D., Hegab, A. E., Soejima, K., Kuroda, A., Ishioka, K., Yasuda, H., Naoki, K., Kagawa, S., Hamamoto, J., Yin, Y., Ornitz, D. M., and Betsuyaku, T. (2015) Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. *J. Pathol.* **235**, 593–605
 42. Guzy, R. D., Stoilov, I., Elton, T. J., Mecham, R. P., and Ornitz, D. M. (2015) Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin. *Am. J. Respir. Cell Mol. Biol.* **52**, 116–128
 43. Yu, C., Wang, F., Jin, C., Huang, X., Miller, D. L., Basilio, C., and McKeehan, W. L. (2003) Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. *Am. J. Pathol.* **163**, 1653–1662
 44. Coffey, E., Newman, D. R., and Sannes, P. L. (2013) Expression of fibroblast growth factor 9 in normal human lung and idiopathic pulmonary fibrosis. *J. Histochem. Cytochem.* **61**, 671–679
 45. Joannes, A., Brayer, S., Besnard, V., Marchal-Sommé, J., Jaillet, M., Mordant, P., Mal, H., Borie, R., Crestani, B., and Mailloux, A. A. (2016) FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts *in vitro*. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **310**, L615–L629
 46. MacKenzie, B., Henneke, I., Hezel, S., Al Alam, D., El Agha, E., Chao, C. M., Quantius, J., Wilhelm, J., Jones, M., Goth, K., Li, X., Seeger, W., Königshoff, M., Herold, S., Rizvanov, A. A., Günther, A., and Bellusci, S. (2015) Attenuating endogenous Fgfr2b ligands during bleomycin-induced lung fibrosis does not compromise murine lung repair. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **308**, L1014–L1024
 47. Ding, B. S., Cao, Z., Lis, R., Nolan, D. J., Guo, P., Simons, M., Penfold, M. E., Shido, K., Rabbany, S. Y., and Rafii, S. (2014) Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. *Nature* **505**, 97–102
 48. Hanumegowda, C., Farkas, L., and Kolb, M. (2012) Angiogenesis in pulmonary fibrosis: too much or not enough? *Chest* **142**, 200–207
 49. Shimbori, C., Bellaye, P. S., Xia, J., Gauldie, J., Ask, K., Ramos, C., Becerril, C., Pardo, A., Selman, M., and Kolb, M. (2016) Fibroblast growth factor-1 attenuates TGF- β 1-induced lung fibrosis. *J. Pathol.* **240**, 197–210
 50. Ramos, C., Montaña, M., Becerril, C., Cisneros-Lira, J., Barrera, L., Ruíz, V., Pardo, A., and Selman, M. (2006) Acidic fibroblast growth factor decreases α -smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **291**, L871–L879
 51. Gupte, V. V., Ramasamy, S. K., Reddy, R., Lee, J., Weinreb, P. H., Violette, S. M., Guenther, A., Warburton, D., Driscoll, B., Minoo, P., and Bellusci, S. (2009) Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice. *Am. J. Respir. Crit. Care Med.* **180**, 424–436
 52. Sugahara, K., Iyama, K., Kuroda, M. J., and Sano, K. (1998) Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. *J. Pathol.* **186**, 90–98
 53. Zheng, B., Zhang, Z., Black, C. M., de Crombrugge, B., and Denton, C. P. (2002) Ligand-dependent genetic recombination in fibroblasts: a potentially powerful technique for investigating gene function in fibrosis. *Am. J. Pathol.* **160**, 1609–1617
 54. Jacob, A. L., Smith, C., Partanen, J., and Ornitz, D. M. (2006) Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. *Dev. Biol.* **296**, 315–328
 55. Yu, K., Xu, J., Liu, Z., Sosic, D., Shao, J., Olson, E. N., Towler, D. A., and Ornitz, D. M. (2003) Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. *Development* **130**, 3063–3074

Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling

Robert D. Guzy, Ling Li, Craig Smith, Samuel J. Dorry, Hyun Young Koo, Lin Chen and David M. Ornitz

J. Biol. Chem. 2017, 292:10364-10378.

doi: 10.1074/jbc.M117.791764 originally published online May 9, 2017

Access the most updated version of this article at doi: [10.1074/jbc.M117.791764](https://doi.org/10.1074/jbc.M117.791764)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 55 references, 18 of which can be accessed free at <http://www.jbc.org/content/292/25/10364.full.html#ref-list-1>